# Transcriptomic profiling reveals distinct molecular signatures among lesion types in hidradenitis suppurativa

**Authors:** Hakim Ben Abdallah, Christine Daugaard, Louise Schøsler, Mads Kirchheiner Rasmussen, Line Kibsgaard, Trine Høgsberg, Claus Johansen, Trine Bertelsen

PMC · DOI: 10.3389/fimmu.2025.1715474 · Frontiers in Immunology · 2026-02-13

## TL;DR

This study identifies unique molecular patterns in different types of hidradenitis suppurativa skin lesions, highlighting the need to consider lesion type in future research and treatment.

## Contribution

The study reveals distinct transcriptomic profiles for different hidradenitis suppurativa lesion types, offering new insights into their molecular mechanisms.

## Key findings

- Inflammatory nodules show increased antigen presentation and CD8+ T cell activity.
- Draining tunnels exhibit heightened IL-1 and IL-17 signaling with upregulated MMPs and downregulated AQPs.
- Non-draining tunnels share some inflammatory features but differ in specific gene expression patterns.

## Abstract

Hidradenitis suppurativa is a painful inflammatory disease characterised by diverse cutaneous lesions that exhibit distinct clinical morphologies. The study aimed to examine the transcriptome of the various hidradenitis suppurativa lesion types.

Transcriptomic analyses were performed using bulk RNA sequencing to examine the various lesion types, including draining tunnels, inflammatory nodules, non-draining tunnels, non-lesional skin from patients with hidradenitis suppurativa and normal skin from healthy individuals.

Principal component and differential expression analyses revealed that these different lesion types exhibit distinct expression profiles while sharing common transcriptional features. Enrichment analysis of exclusively differentially expressed genes for each lesion type showed increased antigen presentation and cytotoxic T cell response in inflammatory nodules, including genes such as CD8B, HLA-C, and HLA-F. In accordance, cell-type enrichment analysis showed an elevated CD8+ T cell signature in inflammatory nodules. Gene set variation analysis demonstrated distinct inflammatory pathway signatures in hidradenitis suppurativa lesions, including heightened IL-1 signalling in draining tunnels with significant upregulation of IL1B and its receptor IL1R, but not IL1A. Furthermore, IL17A and IL17F were significantly increased in draining tunnels, inflammatory nodules, and non-draining tunnels, with IL17F showing the highest expression in draining tunnels. MMP3, MMP8, and MMP10 were preferentially upregulated in draining tunnels, indicating a role in tunnel activity. Moreover, AQP4 and AQP5 were significantly downregulated in both lesional and non-lesional hidradenitis suppurativa skin, suggesting a possible involvement in preclinical pathogenic events.

Distinct molecular signatures specific for each lesion type were identified, which may reflect differences in molecular mechanisms. These findings underscore the importance of distinguishing between lesion types in translational and clinical studies.

## Linked entities

- **Genes:** CD8B (CD8 subunit beta) [NCBI Gene 926], HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107], HLA-F (major histocompatibility complex, class I, F) [NCBI Gene 3134], IL1B (interleukin 1 beta) [NCBI Gene 3553], IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554], IL17A (interleukin 17A) [NCBI Gene 3605], IL17F (interleukin 17F) [NCBI Gene 112744], MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314], MMP8 (matrix metallopeptidase 8) [NCBI Gene 4317], MMP10 (matrix metallopeptidase 10) [NCBI Gene 4319], AQP4 (aquaporin 4) [NCBI Gene 361], AQP5 (aquaporin 5) [NCBI Gene 362]
- **Diseases:** hidradenitis suppurativa (MONDO:0006559)

## Full-text entities

- **Genes:** IL36G (interleukin 36 gamma) [NCBI Gene 56300] {aka IL-1F9, IL-1H1, IL-1RP2, IL1E, IL1F9, IL1H1}, CCL17 (C-C motif chemokine ligand 17) [NCBI Gene 6361] {aka A-152E5.3, ABCD-2, SCYA17, TARC}, CD74 (CD74 molecule) [NCBI Gene 972] {aka CLIP, DHLAG, HLADG, II, Ia-GAMMA, p33}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, IL17D (interleukin 17D) [NCBI Gene 53342] {aka IL-17D}, IL17F (interleukin 17F) [NCBI Gene 112744] {aka CANDF6, IL-17F, ML-1, ML1}, AQP9 (aquaporin 9) [NCBI Gene 366] {aka AQP-9, HsT17287, SSC1, T17287}, MMP11 (matrix metallopeptidase 11) [NCBI Gene 4320] {aka SL-3, ST3, STMY3}, MMP25 (matrix metallopeptidase 25) [NCBI Gene 64386] {aka MMP-25, MMP20, MMP20A, MMPL1, MT-MMP 6, MT-MMP6}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, TSLP (thymic stromal lymphopoietin) [NCBI Gene 85480], HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL17RD (interleukin 17 receptor D) [NCBI Gene 54756] {aka HH18, IL-17RD, IL17RLM, SEF}, IL17RA (interleukin 17 receptor A) [NCBI Gene 23765] {aka CANDF5, CD217, CDw217, IL-17RA, IL17R, IMD51}, IL36A (interleukin 36 alpha) [NCBI Gene 27179] {aka FIL1, FIL1(EPSILON), FIL1E, IL-1F6, IL1(EPSILON), IL1F6}, IL17RE (interleukin 17 receptor E) [NCBI Gene 132014], MMP10 (matrix metallopeptidase 10) [NCBI Gene 4319] {aka SL-2, STMY2}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, IL17RB (interleukin 17 receptor B) [NCBI Gene 55540] {aka CRL4, EVI27, IL17BR, IL17RH1}, IL17B (interleukin 17B) [NCBI Gene 27190] {aka IL-17B, IL-20, NIRF, ZCYTO7}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL37 (interleukin 37) [NCBI Gene 27178] {aka FIL1, FIL1(ZETA), FIL1Z, IL-1F7, IL-1H, IL-1H4}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, IL1RL2 (interleukin 1 receptor like 2) [NCBI Gene 8808] {aka IL-1Rrp2, IL-36R, IL1R-rp2, IL1RRP2}, CCL23 (C-C motif chemokine ligand 23) [NCBI Gene 6368] {aka CK-BETA-8, CKb8, Ckb-8, Ckb-8-1, MIP-3, MIP3}, TRAV24 (T cell receptor alpha variable 24) [NCBI Gene 28659] {aka TCRAV18S1, TCRAV24S1}, HSP90B1 (heat shock protein 90 beta family member 1) [NCBI Gene 7184] {aka ECGP, GP96, GRP94, HEL-S-125m, HEL35, TRA1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, MMP17 (matrix metallopeptidase 17) [NCBI Gene 4326] {aka MMP-17, MT4-MMP, MT4MMP, MTMMP4}, AQP5 (aquaporin 5) [NCBI Gene 362] {aka AQP-5, PPKB}, IL17RC (interleukin 17 receptor C) [NCBI Gene 84818] {aka CANDF9, IL17-RL, IL17RL}, AQP4 (aquaporin 4) [NCBI Gene 361] {aka MIWC, MLC4, WCH4, hAQP4}, AQP7 (aquaporin 7) [NCBI Gene 364] {aka AQP7L, AQPap, GLYCQTL}, MMP28 (matrix metallopeptidase 28) [NCBI Gene 79148] {aka EPILYSIN, MM28, MMP-25, MMP-28}, CD8B (CD8 subunit beta) [NCBI Gene 926] {aka CD8B1, CD8beta, LEU2, LY3, LYT3, Ly-3}, DEFB4A (defensin beta 4A) [NCBI Gene 1673] {aka BD-2, DEFB-2, DEFB102, DEFB2, DEFB4, HBD-2}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, IL25 (interleukin 25) [NCBI Gene 64806] {aka IL17E}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, AQP6 (aquaporin 6) [NCBI Gene 363] {aka AQP2L, KID}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554] {aka CD121A, CRMO3, D2S1473, IL-1R-alpha, IL-1RT1, IL1R}, TRBJ1-5 (T cell receptor beta joining 1-5) [NCBI Gene 28631] {aka TCRBJ1S5, TRBJ15}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, MMP8 (matrix metallopeptidase 8) [NCBI Gene 4317] {aka CLG1, HNC, MMP-8, PMNL-CL}, CCL25 (C-C motif chemokine ligand 25) [NCBI Gene 6370] {aka Ck beta-15, Ckb15, SCYA25, TECK, TECKvar}, TRGV4 (T cell receptor gamma variable 4) [NCBI Gene 6977] {aka TCRGV4, V1S4}, TRDV1 (T cell receptor delta variable 1) [NCBI Gene 28518] {aka hDV101S1}, MMP27 (matrix metallopeptidase 27) [NCBI Gene 64066] {aka MMP-27}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, CCL19 (C-C motif chemokine ligand 19) [NCBI Gene 6363] {aka CKb11, ELC, MIP-3b, MIP3B, SCYA19}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}
- **Diseases:** immune dysregulation (OMIM:614878), cytotoxic (MESH:D064420), CD (MESH:D003424), cutaneous lesions (MESH:D009059), HS (MESH:D017497), inflammatory nodules (MESH:D016606), painful (MESH:D010146), abscess (MESH:D000038), inflammation (MESH:D007249), fibrosis (MESH:D005355)
- **Chemicals:** lipid (MESH:D008055), unsaturated fatty acids (MESH:D005231), HiSCR50 (-), Spesolimab (MESH:C000712973), fatty acid (MESH:D005227), nitrogen (MESH:D009584)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HaCAT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946153/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946153/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946153/full.md

---
Source: https://tomesphere.com/paper/PMC12946153